Senaste nyheterna
Gedea Biotech announces the start of the clinical study VVC2025—first patients enrolled
Gedea Biotech today announced the start of the clinical study VVC2025, following approval from the Swedish Medical Products Agency…
Gedea Biotech strengthens IP portfolio with new European patent for treating infections with GDL
Gedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s intellectual property…
Gedea Biotech strengthens IP portfolio with new US patent for vaginal formulation
Gedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no. 12,496,288). The patent marks an…
Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phase
Gedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The…
Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolled
Gedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical Products Agency…
Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase
Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today announced the appointment of…
Press kit
Klicka för att ladda ner logotyper och bilder
